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Results: 60% of patients reported non presence of fatigue 
before the start of RT Fatigue intensity as assessed with the 
VAS increased gradually during radiotherapy, 14 days after 
the end of radiotherapy, the fatigue intensity was still higher 
than before treatment, but 3 months later, fatigue was lower 
than at the pre-treatment level. Fatigue measured with the 
FAQ did not increase significantly during treatment, but the 
subscores on physical and cognitive fatigue were elevated 
during treatment weeks 4 and 5. IL-1b, IL-6, and TNF-a, and 
hemoglobin levels did not change during therapy. Peripheral 
blood cell levels declined significantly during therapy and 
were still low 3 months after treatment. Until treatment 
week 5, lymphocytes were reduced to almost 50% of their 
initial values. Patients that introduce fatigue had 
significantly lower serum levels of cortisol than the 
nonfatigued patients as well as differences in two 
lymphocyte populations, at 3-6 and 12 months after the end 
of radiotherapy 
 
Conclusion: This study has shown that significant fatigue is 
common in patients receiving breast irradiation and is 
precipitated during radiotherapy in some patients but not 
other. In the patients that show an increase of the fatigue 
during adjuvant RT, fatigue returned to pre-treatment levels 
3 months after treatment. In our study, no evidence was 
found that anxiety, depression, serum levels of IL1-b, IL6, 
TNF-a and hemoglobin levels were correlate with treatment 
induced fatigue. The results of our observation suggest the 
existence of a mechanism among activation of the immune 
system and alteration in cortisol and lymphocyte subsets. 
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Purpose or Objective: There has been recent move within 
the U.K. to contour the nodal CTV for patients receiving 
adjuvant radiotherapy for breast cancer. Axillary 
radiotherapy (ART) following a positive sentinel lymph node 
biopsy is becoming more common for certain groups of 
patients. Organs at risk (OAR) should be delineated and 
considered during the planning process. Body mass index 
(BMI) has been shown to impact upon spinal cord and brachial 
plexus doses in irradiation of the supraclavicular fossa. The 
impact upon the OAR in the axilla has not yet been well 
documented.  
 
Material and Methods: Patients undergoing ART between 
01/04/15–01/10/15 were identified. Non - contrast 
radiotherapy planning CT scans were taken. External beam 
radiotherapy was planned with extended tangents using a 
field in field approach with an additional low weighted 
anterior oblique field if deemed appropriate for adequate 
dose coverage. Dose delivered was 40.05 Gy in 15 
fractions.BMI was calculated by: weight(kg)/height (m)2. 
CTV’s were contoured in accordance with the RTOG 
contouring atlas.OAR including ipsilateral lung, humeral head 
and brachial plexus were delineated. 
 
Results: Fifteen patients were identified. Six patients had a 
BMI between 20–25, 3 between 25–30, 5 between 30–40 and 1 
BMI>40. Mean ipsilateral lung V12 was 10.44% (range 2.3%–
14.33%). Mean V12 did not vary with BMI (BMI 20–25;mean 
V12=9.33%, BMI 25–30; mean V12=8.52%, BMI 30–40;mean 
V12=9.51%, BMI>40 mean V12=6.38%, p=0.55 Chi-Squared). 
The mean humeral head maximum dose was 35.2 Gy (range 
1.2–41.5 Gy). Mean humeral head maximum dose did not vary 
with BMI (BMI 20–25; mean=34.2Gy, BMI 25–30;mean=27.8Gy, 
BMI 30–40; mean=40.3Gy, BMI>40; mean=38.2Gy,p=0.49 t-
test). The ipsilateral brachial plexus D2 mean was15.6Gy 
(range 1.2–37.4 Gy). Mean ipsilateral brachial plexus D2 dose 
did not vary with BMI(p=0.21 t-test). 
 
Conclusion: BMI did not significantly impact upon OAR dosage 
although this series is limited by a small sample size. 
Ipsilateral lung and brachial plexus were comfortably within 
departmental tolerance. A planning risk volume of 10 mm 
around the humeral head has now been adopted within the 
department. It is recognised that intravenous contrast 
provides better quality images for delineating OAR in 
particular for the brachial plexus. However, this impacts 
upon resources in terms of radiographer scanning time. 
Adequate time needs to be allocated in consultant and 
physics teams job plans to enable high quality delineation 
and subsequent radiotherapy plans to be produced.  
 
EP-1172  
Thyroid tolerance in adjuvant supraclavicular fossa nodal 
radiotherapy in breast cancer 
L. Pettit
1Shrewsbury and Telford Hospital NHS Trust, Lingen Davies 
Cancer Center- Royal Shrewsbury Hospital, Shrewsbury, 
United Kingdom 
1, A. Welsh1, S. Khanduri1 
 
Purpose or Objective: Hypothyroidism is the most commonly 
reported long-term toxicity following radiotherapy to 
structures near to the thyroid gland. Emami suggested the 
thyroid gland tolerance as 45Gy (TD 5/5) although a much 
wider range of 10–80 Gy has been reported in the literature. 
When irradiating the supraclavicular fossa (SCF) in adjuvant 
radiotherapy for breast cancer, it is inevitable that the 
thyroid gland will receive a high dose of radiation due to its 
proximity to the target volume. Recently there has been a 
move to CT based delineation of the CTV and organs at risk 
(OAR) in patients requiring nodal radiotherapy for breast 
cancer compared with the previous bony land mark/field 
based techniques. Dose received by the thyroid gland and 
subsequent late toxicity has not yet been well studied in 
breast cancer. 
 
Material and Methods: Patients undergoing external beam 
radiotherapy to the breast or chest wall plus SCF between 
01/04/15–01/10/15 were identified. Radiotherapy planning 
contrast enhanced CT scans were taken. External beam 
radiotherapy was planned with tangents using a field in field 
approach with a matched direct anterior field. A low 
weighted posterior field was added if deemed appropriate for 
adequate dose coverage. Angle corrections were used as 
appropriate. A dose of 40.05 Gy in 15 fractions prescribed at 
depth was employed. CTV’s were contoured in accordance 
with the RTOG contouring atlas.The thyroid gland was 
prospectively delineated and D5% was recorded. 
 
Results: Seventeen patients undergoing adjuvant SCF 
radiotherapy were identified. T stage was as follows: T1:2 
patients,T2:9 patients,T3:4 patients, T4a:1 patient,T4d:1 
patient. N stage; N1:1 patient, N2:14 patients, N3:2 patients. 
Fourteen were hormone receptor positive, 3 hormone 
negative. Twelve were HER2 negative, 5 HER2 positive. Mean 
D5% thyroid was 37.9Gy (range 7–42.7 Gy). Excluding one 
patient with a previous hemi-thyroidectomy, the mean D5% 
thyroid was 39.8 Gy (range 16–42.7 Gy). An abnormality 
requiring referral to a surgeon for was discovered in one 
patient. 
 
Conclusion: Our departmental tolerance for the thyroid 
gland was set as 40Gy (for 2.67Gy per fraction). It is hard to 
achieve this without compromise of the CTV. The effect 
modern chemotherapy/targeted agents may have on this 
prior to receiving radiotherapy is inknown. Baseline TSH 
recording is desirable. Long-term follow up to detect clinical 
or biochemical thyroid dysfunction is needed to inform 
practice but would present challenges with capacity in busy 
oncology departments. 
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